Coronary artery disease (CAD) is an important contributor to morbidity and mortality in patients undergoing liver transplantation (LT). However, the current literature is limited by sampling bias and nondefinitive assessment of CAD. The current study examines the prevalence of CAD via per protocol coronary angiography and its relationship to etiology of liver disease in patients undergoing liver transplantation evaluation (LTE). Data on 228 patients were prospectively collected who had coronary angiography as part of LTE between 2011 and 2014. Coronary angiography was done in all patients age 50 years or with CAD risk factors. CAD was defined as any coronary artery stenosis, whereas stenosis 70% in distribution of 1 or 3 major coronary arteries was considered as single-or triple-vessel disease. CAD was detected in 36.8% of patients, with the highest prevalence among nonalcoholic steatohepatitis (NASH) patients with cirrhosis (52.8%). Prevalence of single-vessel disease was higher among patients with NASH compared with hepatitis C virus (HCV) and alcoholic cirrhosis (15.1% versus 4.6% versus 6.6%; P 5 0.02). Similarly, patients with NASH were more likely to have triple-vessel disease when compared with HCV and alcoholic cirrhosis (9.4% versus 0.9% versus 0%; P 5 0.001). While adjusting for traditional risk factors for CAD, only NASH as etiology of liver disease remained significantly associated with CAD. Complications from diagnostic coronary angiography or percutaneous coronary intervention were low (2.6%). In conclusion, patients undergoing LTE have a high prevalence of CAD, which varies widely depending on etiology of liver cirrhosis. The procedural complications from coronary angiography are low.
Liver transplantation (LT) is the only curative therapy for patients with decompensated cirrhosis. (1) LT is a high-risk surgery performed in a fragile patient population with a nearly 10% 1-year mortality. Thus, a thorough evaluation prior to LT is essential to minimize perioperative risk. (2) An integral component of the liver transplantation evaluation (LTE) is coronary artery disease (CAD) assessment as surgical morbidity and mortality can be as high as 81% and 50%, respectively, in patients with significant CAD undergoing LT. (3) Currently, there are no standardized guidelines regarding CAD assessment in patients undergoing LTE, reflecting the widespread variation in practice across LT centers.
The definitive test of diagnosing CAD is coronary angiography. However, it is often deferred in patients with decompensated cirrhosis due to its invasive nature and perceived increased risk of renal failure, bleeding, and infectious complications. (4) (5) (6) Thus, noninvasive tests such as coronary computed tomography (CT) angiography or chemical stress test are often substituted for coronary angiography. Although these tests have adequate negative predictive value, the positive predictive value is less accurate and therefore does not allow for accurate assessment of CAD among patients undergoing LTE. (7) Studies reporting prevalence of CAD using coronary angiography are limited by sampling bias because coronary angiography is often reserved for patients with either an abnormal noninvasive examination or those with risk factors. (8) (9) (10) Noninvasive CAD assessment in patients with decompensated cirrhosis can be challenging due to debilitated state, body habitus, and concomitant use of b-blockers, which can impact the accuracy of these tests. (11, 12) In fact, noninvasive assessments of CAD can fail to predict major CAD events at the time of LT. (11, 12) In light of these limitations, the available data suggest the prevalence of CAD in patients with cirrhosis ranges from 6% to 26%. (3, (8) (9) (10) 13, 14) However, these studies, too, have several notable limitations including small sample size, (3, 8) noninvasive assessment of CAD, (8, 14) and sampling bias. (8) (9) (10) 14) These studies also fail to report risk factors associated with CAD so that patients can be risk stratified in whom additional invasive workup may be warranted. (3, 8, 13) The evolving indications for LT in the United States also affect the applicability of the published literatures, which were published when viral hepatitis was the leading indication for LT and nonalcoholic steatohepatitis (NASH) was uncommon. (9, 15) However, over the past decade, NASH has become the most common cause of chronic liver disease (CLD) accounting for over 75% of all CLD and is also now the leading indication among new LT wait-list registrants. (16) This shift in causes of chronic liver is important, as an independent relationship between NASH and CAD has been reported, whereas no such relationship exists between hepatitis B and CAD. (17, 18) The largest study to date to evaluate CAD among patients undergoing LTE was conducted in a Korean cohort using coronary CT angiography, where hepatitis B was the leading indication of LTE and NASH was rare. (14) These results are not germane to the US cohort where NASH is the leading etiology of CLD among new patients on the LT waiting list. (16, 19) To overcome these limitations, we conducted this study to describe the following:
1. The distribution of CAD noted on per protocol coronary angiography in patients undergoing LTE. 2. Risk factors associated with CAD. 3. Complications associated with coronary angiography.
Patients and Methods
Data were prospectively collected at Virginia Commonwealth University on patients undergoing elective coronary angiography as part of LTE between January 1, 2011 and December 31, 2014, and then retrospectively analyzed to evaluate the prevalence and distribution of CAD, as well as the complications associated with coronary angiography. The study was approved by the institutional review board at Virginia Commonwealth University. All authors reviewed and approved the manuscript prior to submission.
PATIENT POPULATION
Per institutional policy, all patients over the age of 50 years undergo coronary angiography as part of LTE. In patients < 50 years of age, coronary angiography was reserved for those considered at high risk of CAD based on family history, smoking history, and presence of hypertension, diabetes, obesity, known history of CAD, or abnormal cardiac stress test. Patients undergoing LTE for acute liver failure were excluded from the analysis because they do not undergo routine coronary angiography. Additionally, patients who did not undergo coronary angiography as part of LTE were also excluded.
Patient data collected included demographics; laboratory and radiology results; and clinical and procedural history. Patients were classified per their primary liver disease. In patients with cryptogenic cirrhosis, a diagnosis of NASH was suspected if they had a prior liver biopsy showing steatosis or components of metabolic syndrome in the presence of a negative serological workup for CLDs. Progression to cirrhosis can lead to the reversal of several metabolic comorbidities including improvement in dyslipidemia due to synthetic hepatic failure and hypertension due to a decrease in peripheral vascular resistance. (20, 21) Thus, patients with a prior history of dyslipidemia, hypertension, or medications used to treat these conditions were considered to have them. Presence of type 2 diabetes mellitus (T2DM) was defined per American Diabetes Association guidelines. (22) CORONARY ANGIOGRAPHY All coronary angiographies were performed electively by interventional cardiologists as an outpatient procedure. Coronary procedures were performed according to the standard technique by radial or femoral approach. The nonionic contrast was used for all patients. An AngioSeal was used to close the arteriotomy site. Transfusion to correct coagulopathy was considered in patients with platelet counts <20 3 10 9 /L, international normalized ratio (INR) 2.0, or at the discretion of the treating cardiologist. The degree of stenosis was determined by the cardiologist by visual estimation during the procedure and was defined as the percentage of reduction in diameter, as estimated from a comparison with the diameter of the normal reference vessel proximal to the lesion.
CAD was defined as presence of any stenosis of the coronary arteries. Obstructive disease was defined as stenosis 50%, whereas stenosis < 50% was considered nonobstructive. Significant CAD was defined per Coronary Artery Surgery Study criteria. (23) In patients with obstructive disease, the extent of disease was defined as 1-vessel or multivessel disease. Single-vessel disease was defined as 70% obstruction in 1 of the 3 major coronary artery distributions that includes left anterior descending, circumflex, and right coronary artery (RCA) disease and its main branches. Two-vessel and 3-vessel disease was defined if there was 70% stenosis of 2 and 3 major coronary artery distribution, respectively. A stenosis 50% in the left main artery distribution was considered to be significant. Patients were considered to have 2-or 3-vessel disease based on absence or presence of RCA stenosis. The prevalence of any CAD within the entire cohort was described and stratified further based on etiology of CLD.
Percutaneous coronary intervention (PCI) was performed in patients with obstructive CAD after a collective input by the cardiology, hepatology, and transplant surgery. All patients requiring PCI underwent stenting with bare metal stent (BMS) and were subsequently managed on dual antiplatelet therapy with aspirin and clopidogrel for 4 weeks per protocol. After 4 weeks, patients were transitioned to and maintained on aspirin monotherapy. Patients with extensive disease defined by left main disease (stenosis > 50%), or 3-vessel disease were considered for coronary artery bypass grafting (CABG).
COMPLICATIONS RELATED TO CORONARY ANGIOGRAPHY
Coronary angiography procedure notes were reviewed to identify complications that included renal failure, bleeding, vascular injury, infections, and even death. (4) (5) (6) Clinically significant renal failure was defined as relative (>25%) or absolute (>0.5 mg/dL) in serum creatinine or the need for hemodialysis (HD) within 7 days after coronary angiography. (24) The sustained impact of coronary angiography on renal function was evaluated by comparing serum creatinine, blood urea nitrogen (BUN), and glomerular filtration rate (GFR) before and 4 weeks after angiography within the cohort. All patients on HD prior to coronary angiography were excluded from analysis pertaining to renal failure. Vascular complications were defined as bleeding at the angiography site, hematoma (>5 cm in size), pseudoaneurysm, and arteriovenous fistula that occurred after coronary angiography. In patients who had coronary intervention and required dual antiplatelet therapy, the risk of acute variceal hemorrhage and gastrointestinal bleeding was quantified. Finally, to evaluate the impact of dual antiplatelet agents on subclinical bleeding and anemia, serum hemoglobin in patients on dual antiplatelet agents was compared with those not on antiplatelet therapy.
MAJOR CARDIOVASCULAR EVENTS
In a subset of patients who had a LT, major adverse cardiovascular events (MACEs) were quantified and linked to the presence and severity of CAD prior to transplantation. MACE was defined as cardiac arrest, myocardial infarction (MI), atrial fibrillation, pulmonary embolism, and/or stroke after LT. (25) 
STATISTICAL ANALYSIS
Data are reported as means and standard deviations (SDs), numbers and percentages, or odds ratios (ORs) with 95% confidence intervals (CIs). Means for nonparametric distribution were compared using either Mann-Whitney U test or Kruskal-Wallis test as appropriate. Chi-square test was used to compare proportions between groups consistent of patients with NASH, hepatitis C virus (HCV), and alcoholic cirrhosis. Logistic regression analysis was used to compare the relationship between the presence of CAD and clinical parameters. The independent association between presence of any CAD and clinical variables was assessed by multivariate logistic regression analysis. In the adjusted binary logistic regression model, a priori risk factors for CAD with biological plausibility were used. Risk factors including sex, age, body mass index (BMI), smoking history, and family history were used as covariates. A P value < 0.05 was considered statistically significant. To evaluate the potential effect of contrast-load from coronary angiography on renal function, serum creatinine, GFR, and BUN were compared before and 1 month after coronary angiography using paired sample t tests. Nominal, 2-sided P values were used and considered significant if P < 0.05. Statistical analysis was performed using SPSS (IBM, Armonk, NY).
Results

PATIENT CHARACTERISTICS
A total of 341 patients were referred for LTE from January 1, 2011 to December 31, 2014. Of these, 228 patients met the inclusion criteria (Fig. 1) . The most common reasons for exclusion were deferral of LTE due to clinical improvement and age <50 years in whom coronary angiography was not required (Fig.  1) . Other reasons for exclusion included patients lost to follow-up, death, and patients deemed to be unacceptable candidates due to psychosocial contraindications. A total of 28 patients (12.3% of the total cohort) age < 50 years underwent coronary angiography due to either presence of risk factors or abnormal stress test.
The majority of the cohort was composed of males (64.5%), and the mean age at the time of LTE was 57 6 6 years ( [11] [12] [13] [14] [15] [16] [17] [18] . The leading indication for LTE was decompensated cirrhosis resulting from HCV (47.8%), followed by NASH (23.2%), alcoholic cirrhosis (19.7%), primary sclerosing cholangitis (2.6%), primary biliary cholangitis (PBC; 2.6%), autoimmune hepatitis (1.3%), hepatitis B (1.3%), and other (1.3%). Hepatitis C genotype 3, a known risk factor for metabolic diseases, was present in 9 patients. The prevalence of metabolic comorbidities was much higher within the NASH cohort (Table 1) . For instance, the prevalence of T2DM was 70% versus 24% versus 19% in patients with NASHrelated cirrhosis compared with alcohol and HCVrelated cirrhosis, respectively (P < 0.001). The   FIG. 1 . Overview of the study design, inclusion criteria, and exclusion criteria.
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majority of patients undergoing LTE had a smoking history with 49.1% being former smokers, whereas 7.5% were active smokers. Patients with NASH cirrhosis were less likely to have smoked compared with both HCV and alcoholic cirrhosis (39.6% versus 61.4% and 77.7%, respectively; P 5 0.004).
PREVALENCE AND DISTRIBUTION OF CAD
The distribution of CAD within the cohort and across etiologies of CLD is reported in Table 2 . CAD was present in 84 (36.8%) patients with the highest NOTE: Data are given as n (%) or mean 6 SD. The prevalence of single-vessel CAD was significantly higher in patients with NASH cirrhosis compared with HCV and alcoholic cirrhosis (15.1% versus 4.6% and 6.6%; P 5 0.02; Fig. 2 ). Patients with NASH cirrhosis were more likely to have 3-vessel disease compared with patients with either HCV or alcoholic cirrhosis (9.4% versus 0.9% and 0%, respectively; P 5 0.001).
PREDICTORS OF CAD IN CIRRHOSIS
Using binary logistic regression, the association between the presence of any CAD and clinical parameters was determined. In univariate analysis, traditional risk factors including T2DM (OR, 2.310; 95% CI, 1.316-4.055; P 5 0.004), dyslipidemia (OR, 1.960; 95% CI, 1.069-3.592; P 5 0.03), and hypertension (OR, 2.150; 95% CI, 1.236-3.737; P 5 0.007) were associated with presence of CAD (Table 3) . Interestingly, no association between other known risk factors for CAD (age, sex, smoking history, and family history) and presence of CAD in cirrhosis was noted. Within the entire cohort only NASH (OR, 2.420; 95% CI, 1.287-4.551; P 5 0.006) as an etiology of CLD was associated with CAD. In non-NASH patients, an association between CAD and HCV (OR, 2.458; 95% CI, 1.197-5.049; P 5 0.01) was noted. No association between HCV genotype 3 and CAD was noted. In patients with low risk for CAD (no history of DM, hypertension, obesity, or dyslipidemia [n 5 62]), obstructive CAD and multivessel CAD was present in 14, 9, and 3 patients, respectively. Interestingly, 12 out 14 patients without metabolic comorbidities who had any CAD had HCV as the etiology of CLD.
Adjusting for age, sex, BMI, smoking, and family history, independent predictors of significant CAD were T2DM (OR, 2.363; 95% CI, 1.202-4.644; P 5 0.01), dyslipidemia (OR, 2.089; 95% CI, 1.022-4.270; P 5 0.04), current or prior history of hypertension (OR, 2.200; 95% CI, 1.135-4.265; P 5 0.02), and NASH (OR, 3.121; 95% CI, 1.332-5.321; P 5 0.005) ( Table 3) .
COMPLICATIONS OF CORONARY ANGIOGRAPHY
Of the 228 coronary angiographies performed, a complication was noted in only 6 (2.6%) patients ( Table  4 ). The most common complications included bleeding complications, which occurred in 3 (1.3%) patients. Two of these patients developed catheterization site hematoma. No differences in coagulation profile, degree of thrombocytopenia, or MELD score were noted in patients who had bleeding complications compared with those who did not. Two (0.9%) patients were admitted after the procedure with worsening renal function and required HD. However, no association between clinical or biochemical profile and incidence of renal failure was noted. Two (0.9%) patients were admitted after coronary angiography with sepsis and once again no association was noted with clinical or biochemical profile. A patient developed persistent postprocedural chest pain and repeat urgent coronary angiography showed obtuse marginal 1 (OM1) dissection, which was managed with BMSs. Finally, variceal hemorrhage occurred in a patient within 7 days of coronary angiography, while on dual antiplatelet agents.
One month after coronary angiography, there were no differences in serum creatinine (1.23 6 1.05 versus 1.28 6 0.99; P 5 0.08) or BUN (21.5 6 14.8 versus 22.3 6 14.9; P 5 0.07) compared with values at the time of coronary angiography. The use of diuretics, presence of complications of portal hypertension, age, sex, etiology of CLD, or use of nonselective b-blocker did not have impact on renal function after coronary angiography.
MORTALITY AFTER INTERVENTION FOR CAD
A small minority of patients (n 5 21 or 9.2%) had a PCI. No mortality was noted in patients within 1 month after PCI. Seven (3.1%) patients had multivessel disease and were eligible for CABG. Of these 7 patients, 5 underwent CABG, whereas 2 were deemed poor surgical candidates and turned down for LT. Of the patients undergoing CABG, 2 had NASH, 2 had HCV, and 1 with PBC cirrhosis. A total of 4 of the 5 (80%) patients had hepatic decompensation following CABG and died within 2 weeks after surgery. The mean MELD and MELD-Na of patients who died prior to CABG was 13 and 17, respectively. The only person to survive CABG had clinically improved from a liver perspective with a reduction in MELD score from 17 to 6 at the time of surgery. Finally, 2 patients were rejected for LT consideration based solely on presence of multivessel CAD that would not be amenable to revascularization.
MAJOR CARDIAC OUTCOMES AT LT
Of the 228 that were evaluated, 140 patients were listed and 86 underwent LT. In the patients who had LT, the prevalence of CAD and obstructive CAD was 34.8% (n 5 30) and 16.2% (n 5 14), respectively. Seven MACEs (8%) were noted including atrial fibrillation (n 5 4), intraoperative cardiac arrest (n 5 2), and perioperative non-ST elevation MI (n 5 1). Five patients who had MACE had presence of CAD, whereas 2 did not have any CAD prior to LT. Of the 5 with CAD, 2 had obstructive disease and had revascularization prior to transplant.
Discussion
The optimal algorithm for assessing patients with decompensated cirrhosis for CAD during LTE is unknown due to poorly defined prevalence and risk factors for CAD in this population. A major limitation of the published literature results from lack of per protocol coronary angiographies, thus introducing an inherent sampling bias. The current study narrows this gap in defining the distribution and risk factors associated with CAD using per protocol coronary angiography according to underlying etiology of primary liver disease. Nearly a third of patients undergoing LTE had CAD with the highest prevalence among patients with NASH and HCV cirrhosis. These findings reflect previously published data linking CAD with both NASH (26) (27) (28) (29) (30) and HCV (31) (32) (33) (34) in patients without cirrhosis. Patients without cirrhosis with nonalcoholic fatty liver disease have been shown to have higher disease severity, (35) vulnerable plaque formation, (36) greater burden of lipid core plaques, (29) poor coronary collateral development, (37) and more complex CAD. (38) In patients with NASH cirrhosis, CAD was noted in over half of the study population with nearly a third having obstructive CAD. NASH cirrhosis was also a strong predictor of CAD independent of traditional risk factors including age, sex, BMI, smoking, and family history. Similar to NASH cirrhosis, HCV was also an independent risk factor for presence of CAD, although most patients with HCV cirrhosis had nonobstructive CAD. This is in line with published data supporting increased risk of CAD in patients without cirrhosis with HCV. (32, 34) This risk likely reflects the impact of chronic HCV infection on promoting atherosclerosis via increasing risk of insulin resistance, (39) dyslipidemia, (39) hepatic steatosis, (40) and chronic inflammation. (31) In addition to HCV and NASH as liver-specific risk factors for CAD, several other risk factors were identified that predicted presence of CAD. Traditionally, age, male sex, hypertension, T2DM, dyslipidemia, BMI, family history, and smoking have been associated with CAD risk. (41) In the current study, hypertension, T2DM, and dyslipidemia remained independent predictors of CAD, whereas family history, age, BMI, and smoking did not. Because nearly 90% of the cohort was over the age of 50 years old, the current cohort had skewed age distribution and thus does not reflect the general population. (41) Although BMI and obesity are strong predictors of CAD, (42) these are difficult to measure in patients with decompensated cirrhosis because BMI may be falsely elevated due to fluid retention or altered due to sarcopenia and weight loss. Cigarette smoking is an important, independent risk factor for CAD, (43) but no association between cigarette smoking and CAD was noted in the current study. This could be due to a disproportionate number of patients with smoking history in the non-NASH cohort, who did not have other risk factors for CAD. Conversely, a vast majority of patients with NASH, who are at heightened risk for CAD, did not smoke thus potentially negating the impact of cigarette smoking on CAD. Thus, patients with traditional risk factors (ie, DM, hypertension, dyslipidemia, age), NASH, or hepatitis C cirrhosis should be considered for coronary angiography due to heightened risk of underlying CAD.
Although the gold standard for assessment of CAD, coronary angiography is often avoided in patients with decompensated cirrhosis due to its invasive nature and perceived risks. The risk of bleeding complications and renal failure was low (2.2%) in our study population and not influenced by the degree of thrombocytopenia or coagulopathy. The risk of renal failure requiring HD after coronary angiography was also very low (<1%) and more likely linked to hepatic decompensation rather than contrast-induced renal failure supported further by no change in serum creatinine after coronary angiography. Finally, the risk of coronary artery dissection was noted to be <1% and did not result in any increased mortality. (44) In fact, PCI in patients with decompensated cirrhosis was well tolerated. In contrast, CABG was high risk and associated with a 2-week mortality rate of 80%. This should underscore the importance of either earlier coronary evaluation in patients who may be at risk before their biochemical MELD reaches listing criteria or deferring LT in those with extensive CAD. Extensive CAD at the time of LTE should be considered contraindications for LT because the risk from revascularization surgery far outweighs the benefit of LT. Although only 2 patients were turned down from LT consideration, this may be biased because patients with known extensive CAD may have been triaged without a formal LTE. (46) MACE in the current study was low and reflects what has been reported in literature previously. (45) Our study suggests a potential link between presence of CAD and MACE. However, this does not show causality because the sample size is small and studies with larger sample size are necessary to understand the relationship between CAD and MACE. The likelihood of having a MACE likely reflects a multitude of factors including presence of CAD, heart failure (diastolic, systolic), pulmonary hypertension, valvular heart disease, and intraoperative parameters like blood loss, transfusion of blood products, electrolyte abnormality, and reaction to anesthetics. (46) The current study has some important limitations. Patients < 50 years old were excluded from protocol coronary angiography if they had no risk factors for CAD. In the current study, only 12% of patients had coronary angiography that were <50 years of age, and the prevalence of CAD was less than patients who were 50 years or older. Less than 2% of patients had both coronary angiography and noninvasive evaluation for presence of CAD, thus the current study is unable to evaluate the accuracy of noninvasive cardiac tests in patients with cirrhosis. However, this is beyond the scope of the current study. Also, there were relatively few patients who had LTE performed for indications other than NASH, HCV, and alcoholic cirrhosis. Thus, the current data cannot be extrapolated to all patients undergoing LTE. However, the current study population reflects the typical patient population being evaluated across the country, and the data presented are germane to the LT community. (15, 16) In summary, the current study systematically reports the risk of CAD via coronary angiography in all patients undergoing LTE. NASH and HCV were independent risk factors for presence of CAD. Finally, coronary angiography was well tolerated and can be performed with low risk of complications.
